⦿ Executive Snapshot

• What: Novo Nordisk reported a Q1 2026 adjusted operating profit of DKK 32,858 million, alongside significant sales growth driven by the Wegovy® product line.
• Who: Key players include Novo Nordisk, led by CEO Mike Doustdar, and the US regulatory bodies involved in the approval process.
• Why it matters: The company's financial performance reflects a strong market position in obesity care, highlighting the impact and potential of GLP-1 therapies on chronic disease management.

⦿ Key Developments

• Q1 2026 reported sales increased by 32% at CER, positively impacted by a provision reversal related to the 340B Drug Pricing Program in the US.
• Q1 2026 adjusted sales decreased by 4% at CER, driven by lower realised prices, partly offset by GLP-1 volume growth.
• Wegovy® sales reached DKK 2,256 million in Q1 2026, marking the strongest-ever GLP-1 volume launch in the US with total prescriptions exceeding 2 million since launch.

⦿ Strategic Context

• The launch of the Wegovy® pill in January 2026 signifies a pivotal moment in obesity treatment, establishing Novo Nordisk’s leadership in the GLP-1 market.
• The company’s recent approvals for new products within the obesity and diabetes segments reflect a broader trend towards innovative therapeutic solutions for chronic diseases.

⦿ Strategic Implications

• Immediate market consequences include increased competition for obesity treatments and potential shifts in market share among pharmaceutical companies focused on chronic disease.
• Long-term implications involve the establishment of Wegovy® as a benchmark product, influencing future research and development in peptide-based therapies.

⦿ Risks & Constraints

• Regulatory challenges may arise as Novo Nordisk seeks to expand Wegovy® into international markets outside the US, especially concerning pending approvals.
• Competition from other pharmaceutical companies developing similar obesity and diabetes treatments could impact Novo Nordisk's market share and pricing strategy.

⦿ Watchlist / Forward Signals

• The anticipated launches of Wegovy® outside the US in the second half of 2026 will be critical in assessing the product's global impact and market penetration.
• Future developments in the approval of additional products in the pipeline, such as Wegovy® HD and Awiqli®, will signal the company’s ability to maintain its growth trajectory and innovate in chronic disease management.